The chronic hypoxia seen at high altitude or induced experimentally by environmental changes has several physiological and pathological consequences. The carotid body, the principal sensor of blood oxygen tension, enlarges' and contains increased amounts of dopamine and noradrenaline. 2 The hypoxic drive to ventilation diminishes. 3 In the lung there is constriction of pulmonary arterioles in association with increased muscularisation of their walls, right ventricular hypertrophy, and a rise in pulmonary arterial pressure. 45 In patients with severe obstructive airways disease chronic hypoxaemia when severe is associated with peripheral oedema, often inappropriately termed cor pulmonale. Although the clinical features resemble cardiac failure with a raised jugular venous pressure, hepatomegaly, and gross anasarca, cardiac output is normal or even raised and right ventricular function minimally disturbed. Renal blood flow is reduced by half or more, and this seems to be a critical physiological abnormality, closely correlated with hypoxaemia and hypercapnia, particularly the latter.67
It was hoped that many of these features in patients with hypoxaemic chronic obstructive airways disease would be improved by oxygen therapy designed to restore arterial oxygen tension to at least 8 kPa and arterial oxygen saturation to 90% or more. The benefit so far, however, has been limited. Long term domiciliary oxygen therapy was found to require administration for at least 15 hours a day for benefit to be seen, better results requiring even longer treatment-up to 24 hours a day.89 Survival is increased for some years with long term oxygen therapy but this fails to arrest the decline in airway function or the continuing pathological changes in small pulmonary vessels; benefit in the long term is limited. ' the improved arterial blood gas tensions seen with almitrine are due to an increase in minute ventilation'2 or to improvement in ventilation-perfusion (V/() matching due to selective pulmonary vasoconstriction is still debated'3 (evidence reviewed by Tweney'4) .
Treatment with almitrine causes a rise in arterial oxygen tension of a magnitude similar to that produced by oxygen therapy. Studies of patients with chronic obstructive airways disease'5 using almitrine in a daily dose of 100-200 mg have so far shown some reduction in oedema and reduced exacerbations of illnesses requiring hospital admission. There has, however, been no effect on survival comparable to that seen with long teriit oxygen therapy. Breathlessness has been increased in some patients and decreased in others. Reversible peripheral neuropathy is the most important side effect. This has focused attention on the neurological manifestations of chronic hypoxaemia in patients with obstructive airways disease.
In the trials of long term oxygen, treatment was found to improve neuropsychiatric manifestations, such as depression, quality of life, and emotional behaviour marginally.'6 Patients with hypoxaemic bronchitis were found to have a much greater range of neuropsychological abnormality than matched controls but overt peripheral nerve disorder was not observed (reviewed by Grant and Heaton.'7) The first papers on peripheral nerve function in patients with chronic obstructive airways disease reported physiological disturbance of peripheral nerve function in up to 60% of patients, though there was little clinical evidence of this.'> The disorder was considered to be "subclinical." When peripheral neuropathy was first reported in a small number of bronchitic patients taking almitrine by Chedru et al 21 and Gherardi et al 22 the neurological disturbances were attributed to the drug.
Further studies with almitrine showed that the onset of neuropathy was usually insidious and of mostly a distal sensory neuropathy affecting the lower limbs in particular, with histological and electrophysiological evidence of axonopathy.22 Although the first reports suggested that peripheral nerve pathology might be associated with almitrine with or without additional effects from other respiratory drugs, electrophysiological studies soon began to show that patients with hypoxaemic chronic bronchitis had a similar incidence of such changes whether treated with almitrine or not. (unpublished) ontrol subjects. with lower doses have so far shown a similar -ontrol subjects improvement in arterial oxygen tension with noticeine had at least ably less neurological side effects. The optimal kfter six and 12 therapeutic dose has still to be determined. A threshas no change in old phenomenon has not been observed. asures studied.
The carotid body with its afferent nerve supply d, double blind intact has been shown to be an essential prerequisite lent in patients for the increase in arterial oxygen tension with iitis'3 50 of 344 almitrine in experimental animals" and man.'2 The :corded paraes-enlargement ofthe carotid body, with accumulation of 57(2.2%) in the catecholamines, particularly dopamine, in patients of almitrine in and animals with chronic hypoxaemia, suggests that ig daily. Some almitrine could exert its effects by manipulating the -ntrations well concentration or action of these transmitters. Are the itration of 200-actions ofalmitrine restricted to the carotid body? The concentrations enhancement of hypoxic effects on peripheral nerves oms (figure).
suggests a possible direct effect on this tissue, perhaps rd the results of through hypoxia receptors or by restriction of blood ly of 12 patients supply from endothelial proliferation. In short term experiments no discernible effects ofalmitrine could be observed in chemodectomised animals35 or man.'2 The carotid body is therefore not excluded as an important intermediary or even modulator of hypoxic neural effects. The same consideration might apply to other body tissues, including endothelium. Further studies of the interaction between hypoxia and almitrine on the carotid body and tissues such as lung, kidney, and peripheral nerves are awaited with great interest.
